Pazopanib

91 interactions 6 explained in plain English
Also sold as: Votrient Votrient®
About Pazopanib

Pazopanib is used to treat advanced renal cell carcinoma (RCC, a type of cancer that begins in the cells of the kidneys) in adults. Pazopanib is in a class of medications called kinase inhibitors. It works by slowing or stopping the spread of cancer cells. Read the full Pazopanib drug information page →

Dr. Brian Staiger, PharmD, BCPS
Medically reviewed by Dr. Brian Staiger, PharmD, BCPS · Updated Jun 30, 2026 · Editorial policy · Data sources

Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →

Most serious with: Ketoconazole Topical Inotuzumab Ozogamicin Injection Histrelin Implant Octreotide Lenvatinib Granisetron Transdermal Patch
1 Contraindicated 85 Major 5 Moderate
All (91) Contraindicated (1) Major (85) Moderate (5)

Major

Pazopanib Finerenone Kerendia Increased finerenone exposure and an increased risk of finerenone-related adverse effects Details Pazopanib Flecainide Tambocor® Increased flecainide exposure and increased risk of QT-interval prolongation Details Pazopanib Foscarnet Injection Foscavir An increased risk of QT-interval prolongation Details Pazopanib Fostemsavir Rukobia Increased risk of torsade de pointes Details Pazopanib Galantamine Razadyne An increased risk of QT-interval prolongation Details Pazopanib Gatifloxacin Ophthalmic Zymar® Increased risk of QT interval prolongation Details Pazopanib Gemifloxacin Factive An increased risk of QT interval prolongation Details Pazopanib Glasdegib Daurismo Increased risk of QT interval prolongation Details Pazopanib Goserelin Implant Zoladex Increased risk of QT interval prolongation Details Pazopanib Granisetron Transdermal Patch Sancuso An increased risk of QT interval prolongation Details Pazopanib Granisetron Injection Granisol An increased risk of QT interval prolongation Details Pazopanib Histrelin Implant Supprelin Increased risk of QT interval prolongation Details Pazopanib Hydroxychloroquine Plaquenil Increased risk of QT interval prolongation Details Pazopanib Inotuzumab Ozogamicin Injection Besponsa Increased risk of QT interval prolongation Details Pazopanib Ivabradine Corlanor Increased risk of QT prolongation Details Pazopanib Lanreotide Injection Somatuline Altered exposure to CYP3A4 substrate Details Pazopanib Lansoprazole Prevacid Reduction in pazopanib bioavailability Details Pazopanib Lefamulin Xenleta Increased risk of QT interval prolongation Details Pazopanib Lenvatinib Lenvima Increased risk of QT-interval prolongation Details Pazopanib Letermovir Injection Prevymis Increased CYP3A substrate exposure Details Pazopanib Levofloxacin Levaquin Increased risk of QT interval prolongation Details Pazopanib Levofloxacin Injection Levaquin Increased risk of QT interval prolongation Details Pazopanib Loperamide Diamode Increased loperamide exposure, an increased risk of loperamide-related adverse effects and an increased risk of QT interval prolon... Details Pazopanib Mefloquine Lariam® An increased risk of QT interval prolongation Details Pazopanib Mercaptopurine Purinethol® An increased risk of hepatotoxicity Details Pazopanib Methotrexate Jylamvo Increased methotrexate exposure, an increased risk of methotrexate-related severe adverse reactions, reduced active metabolite for... Details Pazopanib Methotrexate Injection Abitrexate® Increased methotrexate exposure, an increased risk of methotrexate-related severe adverse reactions, reduced active metabolite for... Details Pazopanib Methylergonovine Methergine Increased methylergonovine exposure Details Pazopanib Metronidazole Flagyl An increased risk of QT-interval prolongation Details Pazopanib Metronidazole Injection Flagyl An increased risk of QT-interval prolongation Details Pazopanib Metronidazole Topical MetroCream® An increased risk of QT-interval prolongation Details Pazopanib Metronidazole Vaginal MetroGel® Vaginal An increased risk of QT-interval prolongation Details Pazopanib Mitapivat Aqvesme Reduced CYP3A substrate exposure Details Pazopanib Moxifloxacin Avelox An increased risk of QT-interval prolongation Details Pazopanib Moxifloxacin Injection Avelox An increased risk of QT-interval prolongation Details Pazopanib Moxifloxacin Ophthalmic Moxeza® An increased risk of QT-interval prolongation Details Pazopanib Nifedipine Adalat® Increased NIFEdipine exposure Details Pazopanib Nizatidine Axid® Decreased pazopanib bioavailability Details Pazopanib Octreotide Bynfezia An increased risk of QT interval prolongation Details Pazopanib Octreotide Injection Bynfezia An increased risk of QT interval prolongation Details

Check another drug

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist
Educational information only, not medical advice. Always confirm interactions with your pharmacist or prescriber before making any change to your medications.